Genprex, Inc.
GNPX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001595248
No open-market purchases or sales by Genprex, Inc. insiders were filed in the last 90 days; 27 institutions reported holding it in 13F filings for Q2 2026, worth $154.9K in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Genprex, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 39 | 38 | −1 |
| Shares | 5.96M | 3.83M | −2.13M (−35.7%) |
| Value | $5.42M | $3.64M | −$1.79M (−32.9%) |
New holders (9)
Institutions that held Genprex, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cypress Capital, LLC | 100,000 | $94.9K | 0.03% |
| XTX Topco Ltd | 39,657 | $37.6K | 0.01% |
| Advisory Services Network, LLC | 17,185 | $16.3K | 0.00% |
| Eqis Capital Management, Inc. | 14,846 | $14.1K | 0.00% |
| HighTower Advisors, LLC | 12,078 | $12.0K | 0.00% |
| Nemes Rush Group LLC | 10,000 | $9.49K | 0.00% |
| MCF Advisors LLC | 25 | $24 | 0.00% |
| Signaturefd, LLC | 8 | $8 | 0.00% |
| Sofos Investments, Inc. | 1 | – | – |
Sold out (10)
Institutions that held Genprex, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Armistice Capital, LLC | 1,950,000 | $1.77M |
| Two Sigma Securities, LLC | 77,219 | $70.3K |
| Renaissance Technologies LLC | 51,307 | $47.0K |
| Mariner, LLC | 20,000 | $18.0K |
| Citadel Advisors LLC | 13,282 | $12.1K |
| Price T Rowe Associates Inc | 12,600 | $12.0K |
| David Loasby | 10,000 | $8.30K |
| National Bank of Canada | 850 | $767 |
| TCI Wealth Advisors, Inc. | 300 | $273 |
| Proequities, Inc. | 32 | $29 |